These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 34232223)
41. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies. Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942 [TBL] [Abstract][Full Text] [Related]
42. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. Berman AN; Blankstein R Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838 [TBL] [Abstract][Full Text] [Related]
43. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353 [TBL] [Abstract][Full Text] [Related]
44. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
45. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk. Melita H; Manolis AA; Manolis TA; Manolis AS J Cardiovasc Pharmacol; 2022 Jan; 79(1):e18-e35. PubMed ID: 34694242 [TBL] [Abstract][Full Text] [Related]
46. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Di Fusco SA; Arca M; Scicchitano P; Alonzo A; Perone F; Gulizia MM; Gabrielli D; Oliva F; Imperoli G; Colivicchi F Heart; 2022 Dec; 109(1):18-25. PubMed ID: 35288443 [TBL] [Abstract][Full Text] [Related]
47. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. Duarte Lau F; Giugliano RP JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875 [TBL] [Abstract][Full Text] [Related]
48. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230 [TBL] [Abstract][Full Text] [Related]
49. Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future". Sabouret P; Angoulvant D; Ray KK Arch Cardiovasc Dis; 2020 Mar; 113(3):147-151. PubMed ID: 32205042 [No Abstract] [Full Text] [Related]
50. Biotechnology Approaches for the Treatment of Dyslipidemia. Parolini C Cardiovasc Drugs Ther; 2021 Feb; 35(1):167-183. PubMed ID: 32519066 [TBL] [Abstract][Full Text] [Related]
51. Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective. Jia X; Liu J; Mehta A; Ballantyne CM; Virani SS Cardiovasc Drugs Ther; 2021 Dec; 35(6):1269-1279. PubMed ID: 32997212 [TBL] [Abstract][Full Text] [Related]
52. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. Luo F; Das A; Khetarpal SA; Fang Z; Zelniker TA; Rosenson RS; Qamar A Trends Cardiovasc Med; 2024 May; 34(4):215-222. PubMed ID: 36746257 [TBL] [Abstract][Full Text] [Related]
53. Lipoprotein(a)-antisense therapy. Vogt A Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):51-56. PubMed ID: 30859384 [TBL] [Abstract][Full Text] [Related]
54. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? Gadi R; Figueredo VM J Cardiovasc Med (Hagerstown); 2015 Jan; 16(1):1-10. PubMed ID: 25379719 [TBL] [Abstract][Full Text] [Related]
55. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia. Wiggins BS J Cardiovasc Pharmacol; 2021 Nov; 78(5):e631-e640. PubMed ID: 34738550 [TBL] [Abstract][Full Text] [Related]
56. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484 [TBL] [Abstract][Full Text] [Related]
57. Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)? Schreml J; Gouni-Berthold I Curr Pharm Des; 2017; 23(10):1562-1570. PubMed ID: 28128058 [TBL] [Abstract][Full Text] [Related]
58. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Reyes-Soffer G; Ginsberg HN; Berglund L; Duell PB; Heffron SP; Kamstrup PR; Lloyd-Jones DM; Marcovina SM; Yeang C; Koschinsky ML; Arterioscler Thromb Vasc Biol; 2022 Jan; 42(1):e48-e60. PubMed ID: 34647487 [TBL] [Abstract][Full Text] [Related]